Author/Year | Region | Design | Infection | Organism | Sample size (D/C) | Agea (years) (D/C) | Antibiotics | Antimicrobial susceptibility test (μg/ml) (D/C) | Treatment durationa (days) (D/C) | Follow-up time (days) (D/C) | Outcomesb | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
DCT | Control | |||||||||||
Pascale, 2017 [33] | Italy | retrospective study | VAP (51), HAP (23), BSI (16), SBSI (49), CVCI (18), UTI (12), IAI (19), SSTI (12), MSI (7) | CRKP | 48/96 | D: 55.5 ± 15 C: 61.3 ± 12 | ETP 1 g q12h/2 g q24h MEM 2 g q8h (3 h infusions) | CST GEN TGC monotherapy or combined | CAB ≥1 R 48/96 CST ≤2 S 28/64 GEN ≤2 S 15/72 TGC ≤1 S 16/58 | D: 17 (11.5–25.5) C: 11.5 (7.5–15.5) | 90/90 | ①②③ |
Venugopalan, 2017 [34] | USA | retrospective study | BSI | CRKP | 18/18 | D: 72(61–83) C: 62(48–75) | ETP 1 g q24h DOR 2 g q8h (4 h infusions) | DOR + CST | ETP - DORc 8 (8–32)/− CSTc 8 (0.5–12)/1.25 (0.75–3.5) | D: 12 (7–14) C: 9 (7–12) | 30/30 | ①②③ |
Cancelli, 2018 [35] | Italy | retrospective study | PNA (12), BSI (14), UTI (37), STI (12) | CPCRE | 21/34 | D: 62.28 ± 12.1 C: 61.18 ± 17 | ETP 1 g/d MEM 6 g/d | CST CST + TGC/GEN/RIF/CAB AMG AMG + CAB MEM + FLQ | ETPd 256 R 20/− e MEMd 256 R 20/− e CST R 10/6 TGC R 11/18 RIF - AMG R 8/4 FLQ R 21/31 | D: 39.2 ± 29.5 C: 20.4 ± 14.1 | 60/60 | ①③ |